Who is sponsoring NCT06969001?

NCT06969001 is sponsored by SCAI Therapeutics.

What drugs are being tested in NCT06969001?

Interventions in NCT06969001: SCAI-005 0.04% or placebo, SCAI-005 0.08% or placebo, SCAI-005 0.08% or placebo 2drops.

What condition does NCT06969001 study?

NCT06969001 studies Wet Age Related Macular Degeneration.

Is NCT06969001 still recruiting?

NCT06969001 is currently completed. Last updated 9 September 2025.

Last reviewed 2025-09-09 · How we verify

NCT06969001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

Completed Phase 1 Last updated 9 September 2025

What this trial tests

Phase 1 trial testing SCAI-005 0.04% or placebo in Wet Age Related Macular Degeneration in 48 participants. Completed in 4 September 2025.

Timeline

29 May 2025

Primary endpoint
4 September 2025

4 September 2025

Quick facts

Lead sponsor	SCAI Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	other
Enrollment	48
Start date	29 May 2025
Primary completion	4 September 2025
Estimated completion	4 September 2025
Sites	1 location across South Korea

Drugs / interventions tested

SCAI-005 0.04% or placebo — full drug profile →
SCAI-005 0.08% or placebo — full drug profile →
SCAI-005 0.08% or placebo 2drops — full drug profile →

Conditions studied

Wet Age Related Macular Degeneration — all drugs for Wet Age Related Macular Degeneration →

Sponsor

SCAI Therapeutics — full company profile →

Who can join

Adults 19 to 50, any sex, with Wet Age Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Wet Age Related Macular Degeneration

Currently open trials in the same condition.

NCT06704009 — NT-101 Topical Ophthalmic Solution in Patients With Wet AMD · Phase 1, PHASE2 · active not recruiting

Other SCAI Therapeutics trials

Trials by the same sponsor.

NCT05733624 — Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06969001 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SCAI Therapeutics
Last refreshed: 9 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06969001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing